Search

Your search keyword '"Biological products industry -- Product development"' showing total 10 results
Start Over Descriptor "Biological products industry -- Product development" Publication Year Range This year
10 results on '"Biological products industry -- Product development"'

1. Reports Outline Biotechnology Study Findings from Genentech Inc. (Pop-refine: a Comprehensive Framework for Evaluating and Optimizing Representativeness In Clinical Trials)

Subjects
Genentech Inc. -- Product development, Biological products industry -- Product development, Medical research -- Reports, Medicine, Experimental -- Reports, Biotechnology -- Reports, Clinical trials -- Reports, Physical fitness -- Reports, Health
Abstract

2025 JAN 25 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on Biotechnology are presented in a new report. According to [...]

Published
2025

2. Hanx Biopharma begins patient dosing in Australia for phase 1 trial of HX044 to treat advanced solid tumours

Subjects
Biological products industry -- Product development, Tumors -- Care and treatment, Biological products -- Product development, Immunotherapy, Clinical trials, Pharmaceuticals and cosmetics industries
Abstract

Hanx Biopharmaceuticals, CO. Ltd, an innovative biotechnology company developing next-generation immunotherapies to address the challenges of unmet medical need diseases, announced the first patient dosing in Australia on December 30, [...]

Published
2025

3. Artax Biopharma achieves clinical validation of first-in-class, oral, Nck modulator AX-158 for autoimmune disease in phase 2a study

Subjects
Psoriasis -- Care and treatment, Biological products industry -- Product development, T cells, Clinical trials, Business, News, opinion and commentary
Abstract

Novel breakthrough: first molecule to modulate the fundamental mechanism of T cell activation underlying autoimmune pathology Statistically significant improvements in T cell and psoriasis-related biomarkers in line with PASI improvements [...]

Published
2025

4. Retinitis Pigmentosa Pipeline Assessment 2024: Therapies, Clinical Trials, and Key Companies involved by DelveInsight | Biogen, Neurotech, Ionis Pharma, Nacuity Pharma, Allegro Ophthalmics, ID Pharma

Subjects
Biological products industry -- Product development, Business -- Research, Medical research -- Reports, Medicine, Experimental -- Reports, Clinical trials -- Reports, Retinitis pigmentosa -- Reports, Business, Business, international
Abstract

M2 PRESSWIRE-January 15, 2025-: Retinitis Pigmentosa Pipeline Assessment 2024: Therapies, Clinical Trials, and Key Companies involved by DelveInsight | Biogen, Neurotech, Ionis Pharma, Nacuity Pharma, Allegro Ophthalmics, ID Pharma (C)1994-2025 [...]

Published
2025

5. Acute Kidney Injury Pipeline Analysis 2024: FDA Approvals, Emerging Therapies, and Key Companies involved by DelveInsight | Astellas Pharma, Amniotics, Guard Therapeutics, RegeneRx Biopharma, Cerenis

Subjects
Biological products industry -- Product development, Business -- Research, Medical research -- Reports, Medicine, Experimental -- Reports, Clinical trials -- Reports, Business, Business, international
Abstract

M2 PRESSWIRE-January 15, 2025-: Acute Kidney Injury Pipeline Analysis 2024: FDA Approvals, Emerging Therapies, and Key Companies involved by DelveInsight | Astellas Pharma, Amniotics, Guard Therapeutics, RegeneRx Biopharma, Cerenis (C)1994-2025 [...]

Published
2025

6. Epidermolysis Bullosa Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and Key Companies Involved by DelveInsight | RegeneRx Biopharma, BridgeBio Pharma, Berg Pharma, Holostem Terapie

Subjects
Innovations, Reports, Health aspects, Product development, Clinical trials -- Health aspects -- Reports, Business research -- Health aspects -- Reports, Baricitinib -- Innovations -- Product development, Dupilumab -- Product development -- Innovations, Medical research -- Health aspects -- Reports, Epidermolysis bullosa -- Health aspects -- Reports, Biological products industry -- Product development, Business -- Research, Medicine, Experimental -- Health aspects -- Reports
Abstract

M2 PRESSWIRE-January 14, 2025-: Epidermolysis Bullosa Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and Key Companies Involved by DelveInsight | RegeneRx Biopharma, BridgeBio Pharma, Berg Pharma, Holostem Terapie (C)1994-2025 M2 [...]

Published
2025

7. The NIMML Institute and NImmune Biopharma Announce Publication of Positive First-in-Human Data of NIM-1324, a Phase 2 Candidate for Systemic Lupus Erythematosus, in Clinical and Translational Science

Subjects
Biological products industry -- Product development, Lupus, Systemic lupus erythematosus, Clinical trials, Business, Business, international
Abstract

First-in-human clinical trial of NIM-1324 met all primary and secondary endpoints Daily oral NIM-1324 treatment confirmed as well-tolerated and safe with no dose-limiting toxicities Oral treatment with NIM-1324 validated to [...]

Published
2025

8. Ascites Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | YZY Biopharma, Healthgen Biotech, Grifols Therapeutics, Versantis

Subjects
Biological products industry -- Product development, Medical research, Medicine, Experimental, Ascites, Biotechnology, Clinical trials, Business, Business, international
Abstract

M2 PRESSWIRE-January 7, 2025-: Ascites Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | YZY Biopharma, Healthgen Biotech, Grifols Therapeutics, Versantis (C)1994-2025 M2 COMMUNICATIONS [...]

Published
2025

9. Hanx Biopharmaceuticals reports first patient dosed in Phase 1 clinical trial of HX044

Subjects
Biological products industry -- Product development, Biopharmaceutics -- Product development, Lung cancer, Non-small cell, Clinical trials, Chemistry
Abstract

M2 PHARMA-January 3, 2025-Hanx Biopharmaceuticals reports first patient dosed in Phase 1 clinical trial of HX044 (C)2025 M2 COMMUNICATIONS Chinese biotechnology company Hanx Biopharmaceuticals Co Ltd announced on Thursday the [...]

Published
2025

10. Hanx Biopharmaceuticals reports first patient dosed in Phase 1 clinical trial of HX044

Subjects
Biological products industry -- Product development, Biopharmaceutics -- Product development, Lung cancer, Non-small cell, Clinical trials, Business
Abstract

M2 EQUITYBITES-January 3, 2025-Hanx Biopharmaceuticals reports first patient dosed in Phase 1 clinical trial of HX044 (C)2025 M2 COMMUNICATIONS http://www.m2.co.uk Chinese biotechnology company Hanx Biopharmaceuticals Co Ltd announced on Thursday [...]

Published
2025

Catalog

Books, media, physical & digital resources
See catalog results